1. Home
  2. ARQQ vs FHTX Comparison

ARQQ vs FHTX Comparison

Compare ARQQ & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arqit Quantum Inc.

ARQQ

Arqit Quantum Inc.

HOLD

Current Price

$13.85

Market Cap

315.7M

Sector

Technology

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$4.84

Market Cap

332.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARQQ
FHTX
Founded
2017
2015
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
315.7M
332.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ARQQ
FHTX
Price
$13.85
$4.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$60.00
$11.50
AVG Volume (30 Days)
180.4K
126.7K
Earning Date
01-01-0001
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.32
EPS
N/A
N/A
Revenue
N/A
$30,909,000.00
Revenue This Year
$381.13
$14.62
Revenue Next Year
$212.00
$15.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.75
52 Week Low
$11.00
$2.94
52 Week High
$62.00
$6.95

Technical Indicators

Market Signals
Indicator
ARQQ
FHTX
Relative Strength Index (RSI) 30.13 34.93
Support Level N/A $4.44
Resistance Level $17.81 $5.85
Average True Range (ATR) 0.96 0.37
MACD 0.02 -0.09
Stochastic Oscillator 1.91 15.02

Price Performance

Historical Comparison
ARQQ
FHTX

About ARQQ Arqit Quantum Inc.

Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: